119 related articles for article (PubMed ID: 10365663)
1. Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells.
Medin JA; Takenaka T; Carpentier S; Garcia V; Basile JP; Segui B; Andrieu-Abadie N; Auge N; Salvayre R; Levade T
Hum Gene Ther; 1999 May; 10(8):1321-9. PubMed ID: 10365663
[TBL] [Abstract][Full Text] [Related]
2. Sulfatide and sphingomyelin loading of living cells as tools for the study of ceramide turnover by lysosomal ceramidase--implications for the diagnosis of Farber disease.
Levade T; Tempesta MC; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
Biochem Mol Med; 1995 Apr; 54(2):117-25. PubMed ID: 8581356
[TBL] [Abstract][Full Text] [Related]
3. Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes.
Li CM; Park JH; Simonaro CM; He X; Gordon RE; Friedman AH; Ehleiter D; Paris F; Manova K; Hepbildikler S; Fuks Z; Sandhoff K; Kolesnick R; Schuchman EH
Genomics; 2002 Feb; 79(2):218-24. PubMed ID: 11829492
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of acid ceramidase deficiency in patients with Farber disease.
Bär J; Linke T; Ferlinz K; Neumann U; Schuchman EH; Sandhoff K
Hum Mutat; 2001 Mar; 17(3):199-209. PubMed ID: 11241842
[TBL] [Abstract][Full Text] [Related]
5. Human acid ceramidase gene: novel mutations in Farber disease.
Zhang Z; Mandal AK; Mital A; Popescu N; Zimonjic D; Moser A; Moser H; Mukherjee AB
Mol Genet Metab; 2000 Aug; 70(4):301-9. PubMed ID: 10993717
[TBL] [Abstract][Full Text] [Related]
6. Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies.
Chatelut M; Harzer K; Christomanou H; Feunteun J; Pieraggi MT; Paton BC; Kishimoto Y; O'Brien JS; Basile JP; Thiers JC; Salvayre R; Levade T
Clin Chim Acta; 1997 Jun; 262(1-2):61-76. PubMed ID: 9204210
[TBL] [Abstract][Full Text] [Related]
7. A simple method for screening for Farber disease on cultured skin fibroblasts.
Chatelut M; Feunteun J; Harzer K; Fensom AH; Basile JP; Salvayre R; Levade T
Clin Chim Acta; 1996 Feb; 245(1):61-71. PubMed ID: 8646815
[TBL] [Abstract][Full Text] [Related]
8. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.
Ramsubir S; Nonaka T; Girbés CB; Carpentier S; Levade T; Medin JA
Mol Genet Metab; 2008 Nov; 95(3):133-41. PubMed ID: 18805722
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease.
Koch J; Gärtner S; Li CM; Quintern LE; Bernardo K; Levran O; Schnabel D; Desnick RJ; Schuchman EH; Sandhoff K
J Biol Chem; 1996 Dec; 271(51):33110-5. PubMed ID: 8955159
[TBL] [Abstract][Full Text] [Related]
10. Turnover of endogenous ceramide in cultured normal and Farber fibroblasts.
van Echten-Deckert G; Klein A; Linke T; Heinemann T; Weisgerber J; Sandhoff K
J Lipid Res; 1997 Dec; 38(12):2569-79. PubMed ID: 9458280
[TBL] [Abstract][Full Text] [Related]
11. The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression.
Li CM; Park JH; He X; Levy B; Chen F; Arai K; Adler DA; Disteche CM; Koch J; Sandhoff K; Schuchman EH
Genomics; 1999 Dec; 62(2):223-31. PubMed ID: 10610716
[TBL] [Abstract][Full Text] [Related]
12. Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells.
Levade T; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
J Neurol Sci; 1995 Dec; 134(1-2):108-14. PubMed ID: 8747852
[TBL] [Abstract][Full Text] [Related]
13. Retrovirus vector-mediated correction and cross-correction of lysosomal alpha-mannosidase deficiency in human and feline fibroblasts.
Sun H; Yang M; Haskins ME; Patterson DF; Wolfe JH
Hum Gene Ther; 1999 May; 10(8):1311-9. PubMed ID: 10365662
[TBL] [Abstract][Full Text] [Related]
14. The in situ degradation of ceramide, a potential lipid mediator, is not completely impaired in Farber disease.
Levade T; Tempesta MC; Salvayre R
FEBS Lett; 1993 Aug; 329(3):306-12. PubMed ID: 8365472
[TBL] [Abstract][Full Text] [Related]
15. Retrovirus-mediated transfer and expression of beta-hexosaminidase alpha-chain cDNA in human fibroblasts from G(M2)-gangliosidosis B1 variant.
Teixeira CA; Sena-Esteves M; Lopes L; Sá Miranda MC; Ribeiro MG
Hum Gene Ther; 2001 Sep; 12(14):1771-83. PubMed ID: 11560770
[TBL] [Abstract][Full Text] [Related]
16. [Farber's lipogranulomatosis].
Koga M
Nihon Rinsho; 1995 Dec; 53(12):3009-13. PubMed ID: 8577050
[TBL] [Abstract][Full Text] [Related]
17. A fluorescence-based high-performance liquid chromatographic assay to determine acid ceramidase activity.
He X; Li CM; Park JH; Dagan A; Gatt S; Schuchman EH
Anal Biochem; 1999 Oct; 274(2):264-9. PubMed ID: 10527524
[TBL] [Abstract][Full Text] [Related]
18. Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease.
Tohyama J; Oya Y; Ezoe T; Vanier MT; Nakayasu H; Fujita N; Suzuki K
J Inherit Metab Dis; 1999 Jun; 22(5):649-62. PubMed ID: 10399097
[TBL] [Abstract][Full Text] [Related]
19. Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls.
Momoi T; Ben-Yoseph Y; Nadler HL
Biochem J; 1982 Aug; 205(2):419-25. PubMed ID: 6814427
[TBL] [Abstract][Full Text] [Related]
20. Natural ceramide is unable to escape the lysosome, in contrast to a fluorescent analogue.
Chatelut M; Leruth M; Harzer K; Dagan A; Marchesini S; Gatt S; Salvayre R; Courtoy P; Levade T
FEBS Lett; 1998 Apr; 426(1):102-6. PubMed ID: 9598987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
